Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Teprotumumab Developed by Genmab A/S under Collaboration with Roche Restarts Clinical Development in New Indication


Tuesday, 11 Jun 2013 03:54pm EDT 

Genmab A/S announced that teprotumumab (RG1507), an antibody developed by Genmab under collaboration with Roche, will restart clinical development in a Phase 2 study in patients with active thyroid eye disease. Clinical development will be conducted by River Vision Development Corporation, who licensed teprotumumab from Roche. Under the Company‚Äôs collaboration with Roche, Genmab will receive milestones as well as royalty payments on successful products. River Vision Development Corporation is a private company focused on ophthalmology. 

Company Quote

345.1
5.2 +1.53%
17 Dec 2014